Analgesics are the pain killers that are used to treat mild or severe pain, including musculoskeletal pain, surgical, trauma pain, cancer pain, or another type of pain. Examples of analgesics include codeine, hydrocodone, oxycodone, and methadone. The different types of analgesics are non-opioids and opioids. Non-opioid analgesics are pain relievers available over-the-counter (OTC) and by prescription. They are rapidly being promoted as a desirable, safe, and productive first-line therapeutic alternative to opioid drugs in a range of clinical settings for mild to severe acute and chronic pain. The different types of drugs include prescription analgesics, and OTC analgesics and involve various routes of administration, such as oral, intravenous, rectal, transdermal, and topical. It is used in internal analgesics, and external analgesics and distributed through various channels, such as hospital pharmacies, retail pharmacies, and drug stores. The analgesics market research report is one of a series of new reports from The Business Research Company that provides analgesics market statistics, including analgesics industry global market size, regional shares, competitors with an analgesics market share, detailed analgesics market segments, market trends, and opportunities, and any further data you may need to thrive in the analgesics industry. This analgesics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global analgesics market size will grow from $111.15 billion in 2022 to $115.13 billion in 2023 at a compound annual growth rate (CAGR) of 3.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global analgesics market size is expected to grow to $127.80 billion in 2027 at a CAGR of 2.6%. A significant rise in the prevalence of chronic diseases is driving the analgesics Market. Analgesic drugs, also known as painkillers, are used to treat and reduce chronic or severe pain in the body resulting from various medical conditions. For instance, in September 2022, according to a report shared by WHO, a Switzerland-based health organization, chronic diseases which is sometimes referred to as noncommunicable diseases (NCDs), are conditions that develop over an extended period of time as a result of a combination of genetic, physiological, environmental, and behavioural variables. Noncommunicable diseases (NCDs) account for 41 million annual fatalities, or 74% of all fatalities worldwide. Before the age of 70, 17 million individuals per year pass away from an NCD. These untimely deaths account for 86% of the deaths in low- and middle-income nations. 77% of NCD-related deaths occur in low- and middle-income nations. Therefore, significant rise in the prevalence of chronic disease is driving the growth of the analgesics market. The growth of the analgesics market is restricted by the increasing use of biologics for the treatment of inflammatory and neuropathic pain. Biologics are drugs produced from living organisms and include several components derived from humans, animals, or microorganisms. These drugs may contain protein, modified human hormones, or cells that produce substances that suppress or activate parts of the immune system. Biologics can provide greater efficacy compared to analgesics, which provide effective pain relief to only 50% of the patients, and is thus widely used nowadays. Rising demand for biologics can adversely impact the growth of the Analgesics market. For instance, Pfizer and Lilly were granted approval by the FDA for developing Tanezumab, a biologics medicine. Companies in the analgesics market are increasingly focusing on acquisition as a strategy for growth. Leading analgesic drug manufacturers are acquiring smaller companies to gain a competitive advantage and strengthen their market position. These acquisitions are helping companies to expand geographically and gain specialized expertise in the research and development of new products. For instance, Analgesic Solutions, LLC was acquired by WCG. WCG intends to make use of the superior R&D capability of Analgesic Solutions, LLC to grow and position itself as a market leader in the Analgesic Market. The US Food and Drug Administration (FDA) and the UK's Medicines and Healthcare Products Regulatory Agency are some of the regulatory bodies that regulate the Analgesic Market. For instance, the FDA has provided guidelines on the manufacturing process of analgesics, and safety measures regarding the use of both opioid and non-opioid analgesics. FDA also regulates and monitors the misuse and abuse of opioid analgesics. Opioid analgesics are prohibited from being sold without a proper medical prescription. Similarly, the Medicines and Healthcare Products Regulatory Agency in the UK safeguards the public interest through effective regulation of analgesic drugs. WCG, a US-based pharmaceuticals company, acquired Analgesic Solutions, LLC, for an undisclosed amount. WCG's newest acquisition aims to improve test sensitivity in clinical trials, through advising, novel tools, data science, technology, and specialised training. Analgesic Solutions, LLC, is a US-based pharmaceutical company that specialises in the development of new pain medications. Major players in the analgesics market are Bayer Healthcare, Pfizer, Sanofi, Johnson & Johnson, Novartis AG, GlaxoSmithKline PLC., Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, and Eli Lilly and Company. North America was the largest region in the analgesics market in 2022. Middle East is expected to be the fastest-growing region in the global analgesics market during the forecast period. The regions covered in the global analgesics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the analgesics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The analgesics market consists of sales of codeine, hydrocodone, oxycodone, and methadone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global analgesics market is segmented - 1) By Type: Non-opioids, Opioids 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores 3) By Route of Administration: Oral, Intravenous, Rectal, Transdermal, Topical 4) By Drug Type: Prescription Analgesics, OTC Analgesics 5) By Application: Internal Analgesics, External Analgesics

The antiemetics and antinauseants refer to drugs that are used in the prophylaxis or management of vomiting that results from emetogenic chemotherapy, and for the management of postoperative nausea and vomiting. Antiemetic and antinauseant drugs prevent, control, or treat, nausea and vomiting caused in general or by other medications, frequent motion sickness, infections, stomach flu, or chemotherapy. These drugs reduced the symptoms of nausea or vomiting by blocking signal messages to the part of the brain that controls nausea and vomiting. The main types of drugs in antiemetics and antinauseants are dopamine antagonists, nk1 receptor antagonists, antihistamines (h1 histamine receptor antagonists), cannabinoids, and benzodiazepines, anticholinergics, steroids, 5-ht3 receptor antagonists, and others. A dopamine antagonist also referred to as an anti-dopaminergic or a dopamine receptor antagonist, is a medication that works by blocking dopamine receptors. It is used in chemotherapy, motion sickness, gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and others and is implemented in various sectors such as hospitals, medical centers, clinics, and research institutes. The antiemetics and antinauseants market research report are one of a series of new reports from The Business Research Company that provides antiemetics and antinauseants market statistics, including antiemetics and antinauseants industry global market size, regional shares, competitors with antiemetics and antinauseants market share, detailed antiemetics and antinauseants market segments, market trends and opportunities, and any further data you may need to thrive in the antiemetics and antinauseants industry. This antiemetics and antinauseants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antiemetics and antinauseants market size will grow from $7.76 billion in 2022 to $8.09 billion in 2023 at a compound annual growth rate (CAGR) of 4.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global antiemetics and antinauseants market size is expected to grow to $9.12 billion in 2027 at a CAGR of 3.0%. The antiemetics and antinauseants market is driven by the increase in the prevalence rate of cancer. Chemotherapy is one of the most recommended treatments to cure cancer, and chemotherapy-induced nausea and vomiting (CINV) are some of the side effects of the treatment. Antiemetics can help prevent CINV in about 60%-70% of patients. According to the WHO reports, the incidence of cancer globally has risen to 18.1 million new cases and 9.6 million deaths. According to another report by the Centers for Disease Control and Prevention, about 650,000 cancer patients in the USA receive chemotherapy in an outpatient oncology clinic each year. The CINV caused by chemotherapy treatments is cured by using antiemetic and antinauseant drugs like Dolasetron (Anzemet), Ranitidine (Zantac), and other serotonin 5-HT3 receptor types of antagonists. An increase in the incidence of cancer will increase demand for antiemetics and antinauseants, thereby driving revenue for the market. Lack of awareness about the variety of antiemetic and antinauseant drugs that are available in the market among the practitioners restrains the market. Despite the presence of a range of drugs, the practitioners prescribe similar drugs to treat patients with different conditions of nausea. The popularity of only a few drugs leads to lower demand for other drugs and thus restricts the overall growth of this market. For example, the American Society of Clinical Oncology released its first guideline in the ‘Choosing Wisely’ (CW) campaign to prevent and discourage the overuse of expensive and similar kinds of antiemetic drugs for all ailments. Manufacturers are exploiting nanotechnology in the antiemetics and antinauseants market to deliver therapeutic agents to specifically targeted sites in a controlled manner through Nanomedicine and Nano delivery systems. Nanomedicine is the medical application of nanotechnology which uses nanoparticles to enhance the action of the drug in treatment and nanotechnology is the design, characterization, production, and application of devices, structures, and systems by controlled manipulation of size and shape at the nanometer scale. The antiemetic and antinauseant drug manufacturers are inclining more toward the use of Nanomedicine or Nano drugs to make the drug effective and increase their revenues. For instance, Merck & Co., an American multinational pharmaceutical company manufactured Aprepitant under the brand name Emend. It is the first FDA-approved drug for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) that uses nanotechnology to increase the absorption of the drug more easily and efficiently. The antiemetics and antinauseants market is regulated by government agencies such as US Food and Drug Administration. In the USA, title 21 of the Food and Drug Administration Department of Health and Human Services, U.S. part 336, contains conditions that all Antiemetic and Antinauseant drugs are required to fulfil to remain in the market, such as definitions, regulations, and regulations related to the labelling of the antiemetic drug products. Major players in the antiemetics and antinauseants market are Johnson & Johnson, Sanofi-Aventis, Pfizer, GlaxoSmithKline, Abbott Laboratories, Eli Lilly and Company, Merck, Eisai, Bristol-Myers Squibb, and SRS Pharmaceuticals. North America was the largest region in the drugs for antiemetics and antinauseants market in 2022. The Middle East is expected to be the fastest-growing region in the global antiemetics and antinauseants market. The regions covered in the global antiemetics and antinauseants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antiemetics and antinauseants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antimetics and antinauseants market consists of sales of dopamine, serotonin, neurokinin, histamine, and acetylcholine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antiemetics and antinauseants market is segmented - 1) By Drug: Dopamine antagonists, NK1 receptor antagonist, Antihistamines (H1 histamine receptor antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, 5-HT3 receptor antagonists, Other Drug Types 2) By Application: Chemotherapy, Motion sickness, Gastroenteritis, General anaesthetics, Opioid analgesics, Dizziness, Pregnancy, Food poisoning, Emotional stress, Other Application Types 3) By End Users: Hospital, Medical Center, Clinic, Research Institutes

Anti-parkinson drug is a term used to describe the medications that are mostly used to treat Parkinson's disease. They are not psychiatric medications, so they cannot legally be used to treat mental health issues. However, a doctor or psychiatrist may recommend one of these medications in addition to an antipsychotic to lessen some of the antipsychotic's negative effects. The main class of anti-Parkinson drugs is levodopa/carbidopa, dopamine receptor agonists, monoamine oxidase type b (MAO-b) inhibitors, catechol-o-methyltransferase (COMT)-inhibitors, anticholinergics, and other drugs. Catechol-O-methyltransferase (COMT) inhibitors are a class of drugs used to treat Parkinson's disease symptoms in conjunction with carbidopa-levodopa therapy. The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs. The drugs are administered through oral, injection, and transdermal that are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The antiparkinson drugs market research report is one of a series of new reports from The Business Research Company that provides anti-Parkinson drugs market statistics, including anti-Parkinson drugs industry global market size, regional shares, competitors with an antiparkinson drugs market share, detailed anti-Parkinson drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-Parkinson drugs industry. This antiparkinson drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global anti-parkinson drugs market size will grow from $9.64 billion in 2022 to $10.23 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global anti-parkinson drugs market size is expected to grow to $12.37 billion in 2027 at a CAGR of 4.9%. The increasing geriatric population and surging cases of Parkinson's disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60 cases of Parkinson's disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60. For instance, in June 2020, according to a study by the United Nations, the total number of people age 80 and above is expected to increase from 143 million in 2019 to over 426 million in 2050. Also, in February 2020, Harvard University, a US-based academic university specializing in teaching, learning, and research, will announce that, according to the Parkinson's Foundation, there are more than 10 million people living with Parkinson's disease globally, and this year, there will be close to one million cases in the United States. Degeneration of neurons in the geriatric population and the surge in cases of Parkinson’s disease are therefore driving market growth. Increased government and corporate investment in Parkinson's disease drug R&D is a major trend in the anti-Parkinson drugs market. For instance, in August 2022, the Parkinson’s Foundation, a US-based national organization that provides funding for research and educational resources, will make a $5.7 million investment in 33 projects to speed up cutting-edge research on Parkinson's disease (PD). Through research grants, the Foundation helps scientists carry out creative studies on numerous PD-related topics in an effort to develop novel therapies, treatments, and ultimately a cure for the 10 million people who suffer from this crippling neurological condition worldwide. Hence, increasing investments in Parkinson’s drug development are expected to drive the market for anti-Parkinson's drugs. The high cost of Parkinson’s disease treatment is anticipated to limit the growth of the anti-Parkinson's drug market over the forecast period. According to the Michael J. Fox Foundation for Parkinson’s Research’s statistics, the economic burden of Parkinson’s disease on patients, families, and the federal government is increasing. In the United States, the overall cost of Parkinson’s disease to individuals, families, and government is $51.9 billion annually, with $25.4 billion on direct medical costs (including hospitalization and medication). Thus, the high cost of Parkinson's disease treatment is expected to impact the anti-Parkinson drugs market. Eli Lilly and Company, a US-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of human drugs, paid $1.04 billion for Prevail Therapeutics Inc. in December 2020. Through this acquisition, Prevail's portfolio of clinical-stage and preclinical neuroscience assets will serve as the program's foundation, and the acquisition will introduce a new approach to Lilly's drug discovery and development processes. This will allow Lilly to expand its research efforts, launch a gene therapy program, and increase the drug development and commercialization capabilities of Lilly in the field of neurological disorders. Prevail Therapeutics Inc. is a US-based biotechnology company pioneering in the discovery and development of gene therapies for patients with Parkinson's disease and other neurodegenerative disorders. Major players in the anti-Parkinson drugs market are GlaxoSmithKline PLC., Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc., Mylan, Boehringer Ingelheim, Orion Pharma, ACADIA Pharmaceuticals Inc., Sun Pharma, Wockhardt, Dr. Reddy’s, Intas, US WorldMeds, Zydus Cadila, Cipla, Strides, 1 A Pharma, Upsher-Smith, Lundbeck, Vertical Pharmaceuticals, LLC., Zambon Pharmaceuticals, and M Somerset Pharmaceuticals Inc., and Wockhardt. North America was the largest region in the anti-Parkinson drugs market in 2022. Middle East is expected to be the fastest-growing region in the global anti-parkinson drugs market during the forecast period. The regions covered in the global anti-Parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anti-Parkinson drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The anti-parkinson drugs market consists of sales of catechol-O-methyl transferase [COMT] inhibitors, anticholinergic drugs, and amantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global anti-parkinson drugs market is segmented - 1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-Inhibitors, Anticholinergics, Other Drugs 2) By Route of Administration: Oral, Injection, Transdermal 3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Brain Tumor Drugs Market Definition

The brain tumor drugs market consists of sales of brain tumor drugs and related services by entities (organizations, sole traders and partnerships) that produce brain tumor drugs to diagnose and cure a mass growth of abnormal cells in the human brain. These drugs are either used alone or in combinations, depending on the type, size and location of the tumor. For example, Afinitor (Everolimus), BiCNU (Carmustine), Everolimus, Carmustine, Temozolomide and Avastin (Bevacizumab) are some of the drugs included in this market. The pharmaceutical industry develops drugs to diagnose, treat or prevent diseases. Pharmaceutical drugs are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy, and marketing. Brain tumor drugs manufacturers produce pharmaceutical drugs made from active pharmaceutical ingredients (API) and excipients.

Anesthetics refer to any refer to any substance, including pain, that causes a local or widespread lack of sensation. Anesthesia suppresses reactions to sensory input by acting on the brain or peripheral nervous system. These drugs are used to give a sense of calm to patients through muscle relaxation, which also causes amnesia. The main types of anesthetics are general anesthetics and local anesthetics. A medically induced coma with a lack of defensive reflexes is known as general anesthesia. It is caused by the injection of one or more general anesthetic drugs. The different routes of administration include Inhalation Anaesthesia Drugs, Intravenous Anaesthesia Drugs, and Topical Anaesthesia Drugs and are used in various applications such as General Surgeries, Plastic Surgery, Cosmetic Surgeries, Dental Surgeries, and Other Applications. The anesthetics market research report is one of a series of new reports from The Business Research Company that provides anesthetics market statistics, including anesthetics industry global market size, regional shares, competitors with an anesthetics market share, detailed anesthetics market segments, market trends, and opportunities, and any further data you may need to thrive in the aesthetics industry. This anesthetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global anesthetics market size will grow from $9.97 billion in 2022 to $10.49 billion in 2023 at a compound annual growth rate (CAGR) of 5.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global anesthetics market size is expected to grow to $12.34 billion in 2027 at a CAGR of 4.1%. The increase in the number of surgeries is one of the major drivers of the anesthetics market due to the applications of anesthetic drugs during surgical procedures. This rise is mainly due to increasing incidents of injuries and accidents that require surgeries. For example, according to WHO's Global status report on road safety, the number of road accidents reached 1.35 million, with approximately 64 deaths for every 100,000 vehicles. Stringent guidelines and regulations imposed by regulatory bodies are one the important restraints for the anesthetics market. These guidelines include conducting clinical trials of newly developed drugs, standards related to patient safety, and monitoring of patients under anesthesia. Complying with these guidelines and getting regulatory approvals consumes a lot of time and negatively impacts the growth of the anesthetics market. For example, the American Society of Anesthesiologists imposes various standards that apply to anesthesia care and monitoring of patients including standards for pre-, basic- and post-anesthesia care and monitoring. Increasing consolidation in the form of acquisitions is an emerging trend in the anesthetics market. This is mainly due to the high level of R&D and intellectual property (IP) investment needed to establish companies that manufacture anesthetic drugs. In this regard, mergers and acquisitions are considered a time and cost-effective methods. Some of the notable acquisitions in recent years include the acquisition ofFDHSAnesthesia LLC by CRH Medical Corporation in 2020, the acquisition of Claris Injectables by Baxter for $625 million, the acquisition of GSK's anesthetics portfolio by Aspen for $238.7 million, and acquisition of Hospira by Pfizer for $17 billion. Major players in the anesthetics market are Baxter, Abbott Laboratories, AstraZeneca, F. Hoffmann-La Roche AG, B. Braun Melsungen AG, AbbVie Inc., Hospira, Aspen, BoehringerIngelheim International GmbH and Eisai Co. Ltd. North America was the largest region in the anesthetics market in 2022. Middle East is expected to be the fastest-growing region in the global anesthetics market during the forecast period. The regions covered in the global anesthetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anesthetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The anesthetics market consists of sales of isoflurane, desflurane, sevoflurane, and nitrous oxide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global anesthetics market is segmented - 1) By Type: General Anesthetics, Local Anesthetics 2) By Application: General Surgeries, Plastic Surgery, Cosmetic Surgeries, Dental Surgeries, Other Applications 3) By Route of Administration: Inhalation Anaesthesia Drugs, Intravenous Anaesthesia Drugs, Topical Anaesthesia Drugs 4) By Local Anesthetics: Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Articaine, Benzocaine, Other Local Anesthesia Drugs 5) By General Anesthetics: Propofol, Sevoflurane, Desflurane, Dexmedetomidine, Remifentanil, Midazolam, Other General Anesthesia Drugs

Generic pharmaceuticals refer to a drug that was developed to have the same dosage form, safety, strength, mode of administration, quality, performance attributes, and intended use as an already marketed brand-name drug. The action and clinical benefits of a generic drug are identical to those of a brand-name drug. The three main types of generic pharmaceuticals are biosimilar; simple generic, and super generic. A biosimilar is a biological product that is very similar to a reference biologic and has no clinically significant differences in terms of safety, purity, or potency. The drugs are delivered through oral, injectable, dermal/topical, and inhalers that are used for various therapies such as CNS, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, and oncology. The various distribution channels involved is hospital pharmacies, retail pharmacies, and online pharmacies. The generic pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides generic pharmaceuticals market statistics, including generic pharmaceuticals industry global market size, regional shares, competitors with a generic pharmaceuticals market share, detailed generic pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the generic pharmaceuticals industry. This generic pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global generic pharmaceuticals market grew from $332.43 billion in 2022 to $358.5 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The generic pharmaceuticals market is expected to grow from $453.19 billion in 2027 at a CAGR of 6.0%. The rising incidence of chronic diseases is one of the major drivers of the generic pharmaceutical market. As more individuals are diagnosed with chronic diseases, they look for more medicines for treatment. Branded drugs come at a premium price, while generic drugs are available at a lower cost and have the same chemical composition as branded drugs. The low cost and same chemical composition and strength of generic drugs make a patient buy generic drugs instead of branded drugs. If it is a chronic disease, the treatment goes on for a longer period, and hence, the sales of generic drugs also increase. For instance, according to the WHO (World Health Organization), over the next 10 years, the number of deaths due to chronic disease is projected to increase by 17%. Also, in 2020, almost 3-quarters of all deaths in the world are due to chronic diseases. The lack of awareness about generic drugs is one of the restraints on the generic pharmaceutical market. The high marketing and advertisement of branded drugs overshadow the availability of generic drugs, which are a substitute for expensive branded drugs. Thus, consumers opt for branded drugs even though the generic drugs carry the same chemical formulation as their counter-branded drugs. According to an article published on CVS HEALTH, many doctors and pharmacists preferred to offer branded drugs to their patients over generic drugs. This prevents the patients to go for generic drugs as they develop a preconceived notion of generic drugs not being at par with branded drugs. For example, according to research conducted by Sahana K Hebbar, in the International Journal of Basic & Clinical Pharmacology, out of 100 patients and 50 non-medical staff, 95% of the patients and 60% of the non-medical staff didn't know about generic drugs. Thus, a lack of awareness about the availability of generic drugs hampers the generic pharmaceutical market. 3D printing technology can transform the manufacturing of drugs in the generic pharmaceutical market. 3D printed pharmaceuticals help improve R&D productivity and deliver new benefits to patients. 3D printing allows the manufacturer to produce drugs with customised size, shape, and texture, which is not possible in traditional manufacturing of generic drugs. 3D printing can help the manufacturer to make generic drugs that have different release dates, appearances, and tastes. For example, GlaxoSmithKline (GSK) completed a study where ultraviolet (UV) and 3D printing were used to manufacture tablets to treat Parkinson's disease. Martin Wallace, director of GSK Technology, said that GSK is investing in 3D printing to manufacture pills and tablets. Also, Aprecia pharmaceutical company launched 'ZipDose' technology, which manufactures 3D printed drugs. The drug manufacturers must comply with the CGMP (Current Good Manufacturing Practice) regulations that come under the US Food and Drug Administration (FDA) which includes generic pharmaceuticals. The CGMP regulations require manufacturers to maintain a minimum quality standard for the methods, controls, and facilities used in the manufacturing, packaging, and processing of drug products. Part- 99 of chapter 1 under title 21-Food And Drugs of CFR (Code of Federal Regulations) contains subparts from A to H. The whole part-99 describes the guidelines that need to be followed by drug manufacturers regarding the dissemination of information on human drugs, including biologics, and devices. The guidelines concern the safety, effectiveness, or benefit of use that is not included in the approved labelling for a drug or device approved by the Food and Drug Administration for marketing. The guidelines regulate the information regarding the drugs that should be delivered to the health care practitioner, pharmacy benefit manager, health insurance issuer, group health plan, or federal or state government agency. In January 2020, ANI Pharmaceuticals, Inc., a USA-based integrated specialty pharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceuticals, acquired Commercial and Pipeline Generic Products from American Pharmaceuticals, Ltd. for $52.5M in cash. This acquisition substantially increases ANI Pharmaceuticals, Inc.’s commercial portfolio and late-stage generic pipeline. Amerigen Pharmaceuticals is a USA-based company focused on the development, manufacture, and sale of high-quality generic pharmaceutical products. Major players in the generic pharmaceuticals market are Teva Pharmaceuticals, Mylan NV, Sandoz International GmbH, Hospira (Pfizer Inc.), Sun Pharmaceutical, Lupin Limited, Endo International PLC., Dr Reddy's Laboratories, Apotex Holdings, Fresenius Kabi Ag, Aurbindo Pharma, Aspen Pharmacare, Sanofi, Cipla, Hikma Pharmaceuticals, Stada Arzneimittel, Krka Group, Nichi-Iko Pharmaceutical, Valeant, Zydus Cadila, Merck & Co., Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Nexus Pharmaceuticals, Novo Nordisk, Ranbaxy Laboratories Ltd., Sawai Pharmaceuticals, Novartis AG, Pfizer and Johnson & Johnson Services. North America was the largest region in the generic pharmaceuticals market in 2022. The Middle East is expected to be the fastest-growing region in the global generic pharmaceuticals market during the forecast period. The regions covered in the global generic pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the generic pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The generic pharmaceuticals market consists of sales of paracetamol, cefixime, amoxicillin, and ofloxacin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global generic pharmaceuticals market is segmented - 1) By Therapy: CNS, Cardiovascular, Dermatology, Genitourinary/Harmonal, Respiratory, Rheumatology, Diabetes, Oncology 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Type: Biosimilar, Simple Generic, Super Generic 4) By Drug Delivery: Oral, Inectables, Dermal/Topical, Inhaler

Brain and neuroimaging devices are medical devices used to capture the structure, function, or pharmacology of the brain and locate areas affected by neurological disorders. The main imaging types of brain and neuroimaging devices are functional magnetic resonance imaging (fMRI), computed tomography (CT), positron emission tomography (PET), electroencephalography (EEG), magnetoencephalography (MEG), and others. Positron emission tomography (PET) is a type of imaging technique that measures the metabolic activity of the cells of body tissues using radioactive substances. The various applications of brain and neuroimaging devices are Parkinson's disease, traumatic brain injury, epilepsy, dementia, sleep disorders, and other applications that are used in hospitals, diagnostic centers, and ambulatory surgical centers. The brain and neuroimaging devices market research report is one of a series of new reports from The Business Research Company that provides brain and neuroimaging devices market statistics, including brain and neuroimaging devices industry global market size, regional shares, competitors with a brain and neuroimaging devices market share, detailed brain and neuroimaging devices market segments, market trends and opportunities, and any further data you may need to thrive in the brain and neuroimaging devices industry. This brain and neuroimaging devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global brain and neuroimaging devices market size will grow from $35.49 billion in 2022 to $37.53 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The brain and neuroimaging devices market size is expected to grow from $47.15 billion in 2027 at a CAGR of 5.9%. An increase in the incidence of neurological disorders is expected to drive the market. According to a report by the European Academy of Neurology, 1 in 3 people in 2022 are affected by a neurological disease and the number of deaths due to neurological disorders increased by almost 40% in the last 30 years. Brain and neuroimaging devices are used to diagnose neurological disorders increasing the survival rate and management of the disease. This increasing incidence rate is expected to drive the brain and neuroimaging devices market. The high cost of imaging devices is anticipated to hamper the market for brain and neuroimaging devices. Neurological and cognitive psychology research and design brain-computer interfaces require high-end machines such as Electroencephalography (EEG), Positron Emission Tomography (PET), Functional Magnetic Resonance Imaging (fMRI) among others. These are high-cost devices, for instance, the new 64-slice CT scanners range between $500,000 and $700,000, cost of a PETCT scanner ranges from $225,000 to $750,000, which is not affordable for all hospitals and labs, mainly in developing countries. Thus, the high cost of imaging devices hampers the buying capacity of hospitals and diagnostic labs, hampering the brain and neuroimaging devices market. Companies and researchers are focusing on developing portable brain scanners that are expected to revolutionize brain imaging by lowering the cost of devices, making them affordable and accessible to all. EMVision Medical Devices and researchers at Queensland University have developed a portable brain scanner technology that enables brain scanning to be performed at almost any location. Researchers at University College London have developed a portable MEG brain scanner that is lightweight, worn like just a helmet but can measure brain activity even as people make natural movements, providing improved imaging opportunities for patients with disorders that cause unprompted body movements, such as epilepsy. Major players in the brain and neuroimaging devices market are GE, Siemens, Philips, Canon, Hitachi Medical Systems, Medtronic PLC., EB Neuro S.p.A., Neurosoft, MinFound Medical Systems Co. Ltd., and Elekta. Western Europe was the largest region in the brain and neuroimaging devices market in 2022. North America was the second largest region in the global brain and neuroimaging devices market report. Africa. was the smallest region in the brain and neuroimaging devices market. The regions covered in the global brain and neuroimaging devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the brain and neuroimaging devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The brain and neuroimaging devices market consists of sales of imaging equipment for brain and nerves such as functional magnetic resonance imaging, computed tomography, positron emission tomography (pet), electroencephalography, magnetoencephalography, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global brain and neuroimaging devices market is segmented - 1) By Imaging Type: Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magneto Encephalography (MEG), Other Imaging Types 2) By End-user: Hospitals, Diagnostic Centres, Ambulatory Surgical Centres 3) By Application: Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Other Applications

Antibody-drug conjugates (ADCs) refer to medications that are specifically designed to administer chemotherapy to cancer cells. ADCs deliver chemotherapy via a linker connected to a monoclonal antibody that binds to a specific target expressed on cancer cells.As soon as the ADC binds to its target (a cancer protein or receptor), a cytotoxic chemical is released into the cancer cell. The main types of antibody-drug conjugates are monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different products include Adcertis, Kadcyla, and others and involve various technologies such as immunogen technology, Seattle genetics technology, immunomedics technology, and others. It is used in blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumours, and others, and is implemented in hospitals, clinics, and others. The antibody-drug conjugates (ADCs) market research report is one of a series of new reports from The Business Research Company that provides antibody-drug conjugates (ADCs) market statistics, including antibody-drug conjugates (ADCs) industry global market size, regional shares, competitors with an antibody-drug conjugates (ADCs) market share, detailed antibody-drug conjugates (ADCs) market segments, market trends and opportunities, and any further data you may need to thrive in the antibody-drug conjugates (ADCs) industry. This antibody-drug conjugates (ADCs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.. The global antibody drug conjugates market grew from $5.9 billion in 2022 to $7.2 billion in 2023 at a compound annual growth rate (CAGR) of 22.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antibody drug conjugates market is expected to grow from $16.15 billion in 2027 at a CAGR of 22.4%. The antibody-drug conjugates market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. The rising incidences of cancer are expected to increase the demand for antibody-drug conjugates, driving the market's growth. The challenges involved in the manufacturing of ADCs is acting as a restraint on the antibody drug conjugates market. ADC manufacturing facilities necessitate a significant capital investment as well as extensive specialised training for operators. ADC process development is complicated as it requires optimization of additional process steps that are not present in conventional monoclonal antibody manufacturing, such as the antibody-drug conjugation reaction and subsequent drug substance purification. Also, antibody-drug conjugates must be manufactured in aseptic environments, and operating personnel should be protected from the highly toxic drug compounds, thereby presenting operational difficulties. Manufacturers of antibody-drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For instance, in March 2022, Sanofi, a France-based multinational pharmaceutical and healthcare company, collaborated with a US-based biotechnology company, Seagen Inc., to create up to three cancer targets for antibody-drug conjugates (ADCs), develop them, and market them. The collaboration would make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen. Through this cooperation, candidate medications with the potential to give cancer patients and their families fresh hope would be created via the synergistic combination of molecules and platforms. Manufacturers of antibody-drug conjugates are monitored by various regulatory bodies, such as the Food and Drug Administration in the USA. In the USA, there is no specific regulatory guidance for the industry on ADC development, and the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. The product quality offices at the FDA, such as the Office of Biotechnology Products (OBP) and Office of Pharmaceutical Quality, primarily focus on the manufacturing of the antibody component of the ADC and the control strategy for the antibody intermediate, as well as for the drug substance (DS) and drug product (DP). The small molecule review groups in the Office of Pharmaceutical Quality bear primary responsibility for the review of the adequacy of the payload and linker, conjugation reactions, and aspects of the control strategy. Major players in the antibody-drug conjugates (ADCs) market are Bayer AG, Concortis Biotherapeutics, F. Hoffmann-La Roche Ltd., Immunomedics Inc., Oxford BioTherapeutics, Pfizer Inc., Seattle Genetics Inc., Takeda Pharmaceutical Company Limited, Abbvie Inc., and Astellas Pharma/Agensys. North America was the largest region in the antibody-drug conjugates (ADCs) market in 2022. The Middle East is expected to be the fastest growing region in the global antibody drug conjugates market during the forecast period. The regions covered in the global antibody-drug conjugates (ADCs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antibody-drug conjugates (ADCs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global antibody drug conjugates market is segmented - 1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types 2) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications 3) By Product: Adcertis, Kadcyla, Other Products 4) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology 5) By End User: Hospital, Clinics, Other End Users